What is China SXT Pharmaceuticals' operating income?

China SXT Pharmaceuticals' total operating income in 2026 was -$7.12 million, based on the following breakdown: Total Gross Profit: $248.70 thousand Total Operating Expenses: $7.37 million

China SXT Pharmaceuticals (SXTC) Financials

$2.41 -0.14 (-5.49%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$2.41 0.00 (-0.04%)

As of 05:32 AM Eastern

Compare

Annual Income Statements for China SXT Pharmaceuticals

This table shows China SXT Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Period end date	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	1.11	1.19	1.54	-10	-3.49	-5.31	-5.93	-3.10	-3.30	-6.21
Consolidated Net Income / (Loss)	1.19	1.19	1.54	-10	-2.75	-5.74	-5.93	-3.10	-3.30	-6.21
Net Income / (Loss) Continuing Operations	1.19	1.19	1.54	-10	-3.49	-5.74	-5.93	-3.10	-3.30	-6.21
Total Pre-Tax Income	1.58	1.63	1.79	-10	-2.94	-5.41	-5.93	-3.10	-3.30	-6.21
Total Operating Income	1.60	1.63	1.77	-1.34	-2.20	-5.19	-5.61	-2.52	-2.68	-7.12
Total Gross Profit	2.31	3.40	4.61	2.70	2.84	1.25	0.43	0.55	0.37	0.25
Total Revenue	5.61	7.02	7.01	5.16	4.78	2.60	1.97	1.93	1.74	1.14
Operating Revenue	5.61	7.02	7.01	5.16	4.78	-	1.97	1.93	1.74	1.14
Total Cost of Revenue	2.57	3.62	2.40	2.46	1.94	1.35	1.55	1.37	1.37	0.89
Operating Cost of Revenue	2.57	3.62	2.40	2.46	1.94	1.35	1.55	1.37	1.37	0.89
Total Operating Expenses	1.42	1.77	2.84	4.04	5.04	6.62	5.88	3.07	3.05	7.37
Selling, General & Admin Expense	0.71	1.77	2.84	4.04	3.45	5.52	5.65	2.64	2.76	7.13
Marketing Expense	-	-	-	-	1.59	0.92	0.39	0.43	0.29	0.24
Total Other Income / (Expense), net	-0.04	-0.00	0.02	-9.05	-1.49	-0.22	-0.48	-0.58	-0.62	0.92
Interest Expense	0.04	0.00	0.01	8.97	1.62	0.04	0.48	0.54	0.65	0.06
Other Income / (Expense), net	-0.00	-0.00	0.03	-0.07	0.13	-	-	-0.04	-	0.98
Income Tax Expense	0.40	0.44	0.25	-0.10	-0.19	0.33	0.00	0.00	0.00	0.00
Basic Earnings per Share	$0.06	$0.06	($0.30)	$33.28	($3.82)	($137.92)	($177.84)	($4,285.66)	($348.17)	($9.13)
Weighted Average Basic Shares Outstanding	20M	20M	5.14M	309.11K	719.55K	41.59K	33.37K	723.00	9.49K	679.65K
Diluted Earnings per Share	$0.06	$0.06	($0.30)	-	-	-	($177.84)	($4,285.66)	($348.17)	($9.13)
Weighted Average Diluted Shares Outstanding	20M	20M	5.14M	6.18M	14.39M	40.63M	33.37K	723.00	9.49K	679.65K
Weighted Average Basic & Diluted Shares Outstanding	-	20M	5.14M	6.18M	14.39M	40.63M	11.43M	0.00	0.00	958.08K

No quarterly income statements for China SXT Pharmaceuticals are available.

This table details how cash moves in and out of China SXT Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Period end date	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025	3/31/2026
Net Change in Cash & Equivalents	0.05	0.59	8.63	-2.00	5.29	2.21	1.80	-5.29	6.05	10
Net Cash From Operating Activities	0.29	1.92	0.24	0.93	-1.32	0.27	-0.08	-1.93	-2.35	-4.02
Net Cash From Continuing Operating Activities	0.29	1.92	0.24	0.93	-1.32	0.24	-0.08	-1.93	-2.35	-4.02
Net Income / (Loss) Continuing Operations	1.19	1.19	1.54	-10	-2.75	-5.74	-5.93	-3.10	-3.30	-6.21
Consolidated Net Income / (Loss)	1.19	1.19	1.54	-10	-2.75	-5.74	-5.93	-3.10	-3.30	-6.21
Depreciation Expense	0.09	0.13	0.18	0.33	0.35	0.32	0.25	0.27	0.15	0.14
Non-Cash Adjustments To Reconcile Net Income	-0.05	-0.58	0.06	8.93	2.05	3.31	4.24	1.27	1.29	3.86
Changes in Operating Assets and Liabilities, net	-0.95	1.19	-1.54	1.96	-1.48	1.79	1.36	-0.37	-0.49	-1.82
Net Cash From Investing Activities	-0.19	-1.05	-0.61	-5.50	-5.81	-0.05	-0.01	0.03	0.06	-1.25
Net Cash From Continuing Investing Activities	-0.19	-1.05	-0.61	-5.50	-5.81	-0.05	-0.01	0.03	0.06	-1.25
Purchase of Property, Plant & Equipment	-0.18	-0.44	-0.54	-0.13	-	-	-	-0.01	-0.00	0.00
Acquisitions	-0.01	-0.02	-0.01	0.00	-0.08	-0.06	-0.07	0.00	0.00	-1.25
Sale of Property, Plant & Equipment	-	-	-	-	-	-	0.00	0.00	0.07	0.00
Sale and/or Maturity of Investments	-	-	-	-	-	0.02	0.06	0.03	0.00	0.00
Net Cash From Financing Activities	-0.05	-0.31	9.04	3.02	12	1.60	2.94	-2.62	8.40	14
Net Cash From Continuing Financing Activities	-0.05	-0.31	9.04	3.02	12	1.63	2.94	-2.62	8.40	14
Repayment of Debt	-0.05	-0.31	2.48	-6.50	12	-4.29	-3.28	-4.12	3.79	-0.38
Issuance of Debt	0.00	0.00	0.07	9.96	0.00	2.80	4.03	1.50	1.85	0.52
Other Financing Activities, net	-	0.00	0.00	-0.44	0.00	-	2.19	0.00	2.76	14
Effect of Exchange Rate Changes	-0.00	0.04	-0.04	-0.47	-	-	-	-0.77	-0.07	0.88
Cash Interest Paid	0.00	0.02	0.05	0.01	0.00	0.00	0.01	0.02	0.02	0.02

No quarterly cash flow statements for China SXT Pharmaceuticals are available.

This table presents China SXT Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025	2026
Period end date	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025	3/31/2026
Total Assets	7.66	17	22	35	34	30	23	22	35
Total Current Assets	6.10	16	20	23	22	20	14	21	35
Cash & Equivalents	0.56	9.13	7.29	13	16	17	12	18	28
Restricted Cash	0.10	0.16	0.00	0.03	0.05	0.00	0.01	0.03	0.00
Accounts Receivable	2.74	4.18	6.16	6.09	4.91	1.34	1.31	2.14	5.08
Inventories, net	1.49	1.33	1.05	1.38	1.07	0.58	0.81	1.13	2.96
Prepaid Expenses	0.91	0.71	4.62	1.86	0.86	0.23	0.03	0.32	0.37
Plant, Property, & Equipment, net	0.86	1.16	1.57	1.43	1.23	0.96	0.33	0.18	0.12
Total Noncurrent Assets	0.69	0.72	0.49	9.88	9.87	9.07	18	0.37	0.25
Intangible Assets	0.06	0.06	0.05	0.05	0.04	0.03	0.02	0.01	0.01
Other Noncurrent Operating Assets	0.63	0.65	0.33	9.51	9.83	9.04	18	0.35	0.24
Total Liabilities & Shareholders' Equity	7.66	17	22	35	34	30	23	22	35
Total Liabilities	4.37	6.36	12	19	17	15	9.20	6.22	5.05
Total Current Liabilities	4.37	6.32	12	19	17	14	8.90	6.01	4.35
Short-Term Debt	0.39	0.26	6.69	0.04	2.05	0.18	0.60	0.72	0.36
Accounts Payable	2.82	4.86	4.18	17	5.01	1.38	1.28	1.16	0.50
Accrued Expenses	-	-	-	-	-	3.14	2.77	2.94	3.30
Customer Deposits	-	-	-	-	-	0.11	0.21	0.05	0.02
Current Deferred Revenue	0.29	0.06	0.30	0.26	0.08	0.17	0.19	0.06	0.10
Current Deferred & Payable Income Tax Liabilities	0.87	1.06	0.99	1.16	1.17	1.10	1.05	1.03	0.00
Other Current Liabilities	0.00	0.08	0.11	0.47	8.82	11	2.21	0.12	0.14
Total Noncurrent Liabilities	0.00	0.04	0.04	0.01	0.00	0.61	0.77	0.33	0.70
Long-Term Debt	0.00	0.04	0.04	0.01	0.00	0.12	0.12	0.10	0.64
Other Noncurrent Operating Liabilities	-	-	-	-	0.00	0.50	0.65	0.23	0.11
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	3.29	11	9.40	16	16	15	14	15	30
Total Preferred & Common Equity	3.29	11	9.40	16	16	15	14	15	30
Total Common Equity	3.29	11	9.40	16	16	15	14	15	30
Common Stock	1.48	7.97	17	25	31	37	40	45	64
Retained Earnings	1.54	3.08	-7.20	-9.95	-16	-22	-25	-28	-34
Accumulated Other Comprehensive Income / (Loss)	0.26	0.05	-0.59	0.53	0.96	-0.20	-1.03	-1.08	-0.20

No quarterly balance sheets for China SXT Pharmaceuticals are available.

This table displays calculated financial ratios and metrics derived from China SXT Pharmaceuticals' official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Period end date	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025	3/31/2026
DEI Shares Outstanding	0.00	0.00	22,706,701.00	34,667,707.00	15,525,094.00	81,255,736.00	11,434,129.00	0.00	0.00	958,077.00
DEI Adjusted Shares Outstanding	0.00	0.00	9.00	14.00	26.00	135.00	381.00	0.00	0.00	958,077.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	171,025.22	-734,848.00	-134,306.65	-39,316.59	-15,576.83	0.00	0.00	-6.48
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	25.05%	-0.10%	-26.38%	-7.45%	-45.53%	-24.23%	-2.19%	-9.73%	-34.63%
EBITDA Growth	0.00%	3.54%	12.49%	-154.77%	-12.16%	-254.91%	-24.26%	57.42%	-10.86%	-137.22%
EBIT Growth	0.00%	1.87%	10.33%	-178.75%	-46.25%	-150.80%	-8.05%	54.45%	-4.94%	-129.14%
NOPAT Growth	0.00%	-0.89%	27.66%	-161.75%	-63.82%	-136.21%	-8.05%	55.15%	-6.57%	-165.73%
Net Income Growth	0.00%	0.21%	29.61%	-768.38%	73.29%	-108.72%	-3.46%	47.79%	-6.62%	-87.83%
EPS Growth	0.00%	0.00%	29.61%	0.00%	0.00%	0.00%	0.00%	47.79%	-6.62%	97.38%
Operating Cash Flow Growth	0.00%	555.25%	-87.54%	290.58%	-240.92%	120.38%	-130.10%	-2,287.47%	-21.64%	-71.30%
Free Cash Flow Firm Growth	0.00%	0.00%	232.52%	-417.14%	160.78%	-183.54%	195.48%	-593.29%	162.28%	-196.93%
Invested Capital Growth	0.00%	0.00%	-29.69%	317.16%	-70.06%	9.66%	-263.24%	349.48%	-112.40%	414.30%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	41.19%	48.46%	65.77%	52.37%	59.44%	48.10%	21.62%	28.73%	21.11%	21.85%
EBITDA Margin	30.25%	25.04%	28.20%	-20.98%	-25.43%	-165.68%	-271.72%	-118.29%	-145.26%	-527.12%
Operating Margin	28.54%	23.25%	25.24%	-25.98%	-45.99%	-199.43%	-284.40%	-130.42%	-153.97%	-625.89%
EBIT Margin	28.48%	23.20%	25.62%	-27.41%	-43.31%	-199.43%	-284.40%	-132.45%	-153.97%	-539.70%
Profit (Net Income) Margin	21.11%	16.92%	21.95%	-199.29%	-57.52%	-220.43%	-301.00%	-160.67%	-189.77%	-545.24%
Tax Burden Percent	75.00%	72.96%	85.92%	99.02%	93.45%	106.07%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	98.85%	99.95%	99.71%	734.31%	142.12%	104.21%	105.84%	121.31%	123.25%	101.03%
Effective Tax Rate	25.00%	27.04%	14.08%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	79.05%	59.25%	-17.14%	-26.78%	-130.97%	0.00%	-49.74%	-36.25%	-317.66%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	81.50%	58.84%	178.61%	-9.34%	-115.30%	0.00%	-37.31%	-21.24%	-311.86%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-6.76%	-37.86%	-83.19%	5.11%	95.55%	0.00%	28.08%	13.76%	290.17%
Return on Equity (ROE)	0.00%	72.29%	21.39%	-100.32%	-21.67%	-35.42%	-38.15%	-21.65%	-22.50%	-27.49%
Cash Return on Invested Capital (CROIC)	0.00%	-120.95%	94.11%	-139.79%	81.06%	-140.19%	0.00%	-154.98%	0.00%	-240.11%
Operating Return on Assets (OROA)	0.00%	21.27%	14.30%	-7.22%	-7.36%	-15.24%	-17.77%	-9.70%	-11.97%	-21.77%
Return on Assets (ROA)	0.00%	15.51%	12.25%	-52.53%	-9.77%	-16.85%	-18.81%	-11.76%	-14.75%	-22.00%
Return on Common Equity (ROCE)	0.00%	72.29%	21.39%	-100.32%	-21.67%	-35.42%	-38.15%	-21.65%	-22.50%	-27.49%
Return on Equity Simple (ROE_SIMPLE)	0.00%	36.14%	13.86%	-109.43%	-17.22%	-34.92%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	1.20	1.19	1.52	-0.94	-1.54	-3.63	-3.93	-1.76	-1.88	-4.99
NOPAT Margin	21.41%	16.97%	21.68%	-18.19%	-32.19%	-139.60%	-199.08%	-91.30%	-107.78%	-438.12%
Net Nonoperating Expense Percent (NNEP)	0.00%	-2.45%	0.41%	-195.75%	-17.44%	-15.67%	-12.20%	-12.42%	-15.01%	-5.80%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-26.20%	-12.02%	-11.54%	-16.24%
Cost of Revenue to Revenue	45.78%	51.54%	34.23%	47.63%	40.57%	51.90%	78.38%	71.27%	78.89%	78.15%
SG&A Expenses to Revenue	12.65%	25.21%	40.53%	78.35%	72.20%	212.00%	286.37%	136.67%	158.43%	626.29%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	25.29%	25.21%	40.53%	78.35%	105.42%	254.50%	298.44%	159.15%	175.08%	647.74%
Earnings before Interest and Taxes (EBIT)	1.60	1.63	1.80	-1.41	-2.07	-5.19	-5.61	-2.55	-2.68	-6.14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1.70	1.76	1.98	-1.08	-1.21	-4.31	-5.36	-2.28	-2.53	-6.00
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	3.10	3,126.75	1.35	1.00	0.26	0.78	0.06	0.01	0.00
Price to Tangible Book Value (P/TBV)	0.00	3.16	3,144.04	1.36	1.00	0.27	0.79	0.06	0.01	0.00
Price to Revenue (P/Rev)	1.81	1.45	4,953.09	2.46	3.34	1.67	5.84	0.40	0.08	0.00
Price to Earnings (P/E)	9.18	8.58	22,564.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	10.90%	11.66%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	3.29	16,388.59	1.38	0.99	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	1.41	4,951.81	2.35	0.55	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	5.64	17,558.19	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	6.09	19,326.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	8.32	22,838.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	5.16	145,164.56	13.01	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	14,378.91	0.00	0.57	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.12	0.03	0.72	0.00	0.12	0.02	0.05	0.05	0.03
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.02
Financial Leverage	0.00	-0.08	-0.64	-0.47	-0.55	-0.83	-1.06	-0.75	-0.65	-0.93
Leverage Ratio	0.00	2.33	1.75	1.91	2.22	2.10	2.03	1.84	1.53	1.25
Compound Leverage Factor	0.00	2.33	1.74	14.03	3.15	2.19	2.15	2.23	1.88	1.26
Debt to Total Capital	0.00%	10.49%	2.65%	41.70%	0.27%	11.08%	1.96%	4.92%	5.05%	3.26%
Short-Term Debt to Total Capital	0.00%	10.49%	2.29%	41.47%	0.23%	11.08%	1.17%	4.13%	4.46%	1.16%
Long-Term Debt to Total Capital	0.00%	0.00%	0.37%	0.23%	0.04%	0.00%	0.79%	0.80%	0.59%	2.10%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	89.51%	97.35%	58.30%	99.73%	88.92%	98.04%	95.08%	94.95%	96.74%
Debt to EBITDA	0.00	0.22	0.15	-6.21	-0.04	-0.47	-0.05	-0.32	-0.32	-0.17
Net Debt to EBITDA	0.00	-0.16	-4.55	0.52	10.96	3.14	3.19	4.98	6.84	4.53
Long-Term Debt to EBITDA	0.00	0.00	0.02	-0.03	-0.01	0.00	-0.02	-0.05	-0.04	-0.11
Debt to NOPAT	0.00	0.32	0.20	-7.16	-0.03	-0.56	-0.07	-0.41	-0.44	-0.20
Net Debt to NOPAT	0.00	-0.23	-5.91	0.60	8.66	3.72	4.35	6.45	9.22	5.45
Long-Term Debt to NOPAT	0.00	0.00	0.03	-0.04	0.00	0.00	-0.03	-0.07	-0.05	-0.13
Altman Z-Score	0.00	3.57	3,276.57	0.59	0.21	-0.74	-0.91	-1.45	-1.28	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	1.40	2.47	1.60	1.25	1.31	1.35	1.60	3.54	7.93
Quick Ratio	0.00	0.82	2.12	1.10	1.05	1.20	1.29	1.50	3.37	7.65
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-1.82	2.41	-7.66	4.65	-3.89	3.71	-18	11	-11
Operating Cash Flow to CapEx	163.55%	440.39%	44.64%	714.04%	0.00%	0.00%	0.00%	-27,297.93%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	-2,339.16	466.72	-0.85	2.88	-105.96	7.79	-33.65	17.59	-175.57
Operating Cash Flow to Interest Expense	7.26	2,464.91	46.23	0.10	-0.82	7.31	-0.17	-3.54	-3.62	-63.80
Operating Cash Flow Less CapEx to Interest Expense	2.82	1,905.19	-57.33	0.09	-0.82	7.31	-0.17	-3.56	-3.52	-63.80
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.92	0.56	0.26	0.17	0.08	0.06	0.07	0.08	0.04
Accounts Receivable Turnover	0.00	2.57	2.03	1.00	0.78	0.47	0.63	1.45	1.01	0.32
Inventory Turnover	0.00	2.42	1.70	2.07	1.60	1.10	1.88	1.98	1.42	0.44
Fixed Asset Turnover	0.00	8.14	6.94	3.78	3.18	1.96	1.80	2.99	6.86	7.70
Accounts Payable Turnover	0.00	1.28	0.62	0.54	0.19	0.12	0.48	1.03	1.13	1.07
Days Sales Outstanding (DSO)	0.00	142.29	180.02	365.40	467.69	771.60	579.31	251.66	361.80	1,156.97
Days Inventory Outstanding (DIO)	0.00	150.74	214.48	176.22	228.49	330.68	194.31	184.20	257.62	838.32
Days Payable Outstanding (DPO)	0.00	284.88	584.16	670.93	1,961.55	2,927.21	754.55	352.83	323.92	339.81
Cash Conversion Cycle (CCC)	0.00	8.15	-189.65	-129.31	-1,265.38	-1,824.93	19.07	83.03	295.50	1,655.48
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	3.01	2.12	8.84	2.65	2.90	-4.74	12	-1.46	4.60
Invested Capital Turnover	0.00	4.66	2.73	0.94	0.83	0.94	-2.15	0.54	0.34	0.73
Increase / (Decrease) in Invested Capital	0.00	3.01	-0.89	6.72	-6.19	0.26	-7.64	17	-13	6.07
Enterprise Value (EV)	0.00	9.91	34,722	12	2.63	-9.18	-5.55	-11	-17	0.00
Market Capitalization	10	10	34,731	13	16	4.35	12	0.77	0.14	0.00
Book Value per Share	$0.00	$0.16	$2.16	$0.41	$0.46	$1.06	$0.36	$1.22	$1,627.12	$43.71
Tangible Book Value per Share	$0.00	$0.16	$2.15	$0.41	$0.46	$1.06	$0.36	$1.22	$1,625.88	$43.70
Total Capital	0.00	3.67	11	16	16	18	15	15	16	31
Total Debt	0.00	0.39	0.30	6.72	0.04	2.05	0.29	0.72	0.82	1.00
Total Long-Term Debt	0.00	0.00	0.04	0.04	0.01	0.00	0.12	0.12	0.10	0.64
Net Debt	0.00	-0.27	-8.99	-0.56	-13	-14	-17	-11	-17	-27
Capital Expenditures (CapEx)	0.18	0.44	0.54	0.13	0.00	0.00	0.00	0.01	-0.06	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	1.46	0.24	6.77	-8.67	-8.19	-12	-6.14	-2.12	2.34
Debt-free Net Working Capital (DFNWC)	0.00	2.12	9.53	14	4.69	7.38	5.20	5.94	16	31
Net Working Capital (NWC)	0.00	1.73	9.27	7.37	4.65	5.33	5.02	5.33	15	30
Net Nonoperating Expense (NNE)	0.02	0.00	-0.02	9.35	1.21	2.10	2.01	1.34	1.43	1.22
Net Nonoperating Obligations (NNO)	0.00	-0.27	-8.99	-0.56	-13	-14	-19	-2.11	-17	-25
Total Depreciation and Amortization (D&A)	0.10	0.13	0.18	0.33	0.85	0.88	0.25	0.27	0.15	0.14
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	20.76%	3.36%	131.19%	-181.44%	-314.84%	-617.18%	-318.45%	-121.79%	205.56%
Debt-free Net Working Capital to Revenue	0.00%	30.13%	135.88%	272.35%	98.18%	283.47%	263.72%	307.80%	919.59%	2,681.39%
Net Working Capital to Revenue	0.00%	24.65%	132.15%	142.81%	97.40%	204.83%	254.82%	276.45%	877.96%	2,650.18%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$150.00	($832.00)	$95.50	$0.00	($177.80)	($4,286.40)	($348.15)	($9.13)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	10.28K	17.33K	31.05K	0.00	33.37K	723.00	9.49K	679.65K
Adjusted Diluted Earnings per Share	$0.00	$0.00	$150.00	($832.00)	$95.50	$0.00	$0.00	$0.00	($348.15)	($9.13)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	10.28K	17.33K	31.05K	0.00	57.17K	0.00	9.49K	679.65K
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($832.00)	$95.50	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	11.35K	12.36K	28.78K	0.00	57.17K	0.00	0.00	958.08K
Normalized Net Operating Profit after Tax (NOPAT)	1.20	1.19	1.52	-0.94	-1.54	-3.63	-3.93	-1.76	-1.88	-4.99
Normalized NOPAT Margin	21.41%	16.97%	21.68%	-18.19%	-32.19%	-139.60%	-199.08%	-91.30%	-107.78%	-438.12%
Pre Tax Income Margin	28.15%	23.19%	25.55%	-201.26%	-61.56%	-207.82%	-301.00%	-160.67%	-189.77%	-545.24%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	39.58	2,090.45	347.24	-0.16	-1.28	-141.43	-11.76	-4.69	-4.14	-97.55
NOPAT to Interest Expense	29.75	1,528.79	293.84	-0.10	-0.95	-99.00	-8.23	-3.23	-2.89	-79.19
EBIT Less CapEx to Interest Expense	35.14	1,530.74	243.68	-0.17	-1.28	-141.43	-11.76	-4.71	-4.04	-97.55
NOPAT Less CapEx to Interest Expense	25.31	969.07	190.28	-0.12	-0.95	-99.00	-8.23	-3.25	-2.80	-79.19
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

No quarterly metrics and ratios for China SXT Pharmaceuticals are available.

Financials Breakdown Chart

China SXT Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, China SXT Pharmaceuticals' fiscal year ends in March. Their fiscal year 2026 ended on March 31, 2026.

China SXT Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$6.21 million in 2026, falling from $1.19 million in 2017. The previous period was -$3.30 million in 2025. Find out what analysts predict for China SXT Pharmaceuticals in the coming months.

China SXT Pharmaceuticals' total operating income in 2026 was -$7.12 million, based on the following breakdown:

Total Gross Profit: $248.70 thousand
Total Operating Expenses: $7.37 million

Over the last 9 years, China SXT Pharmaceuticals' total revenue changed from $5.61 million in 2017 to $1.14 million in 2026, a change of -79.7%.

China SXT Pharmaceuticals' total liabilities were at $5.05 million at the end of 2026, a 18.9% decrease from 2025, and a 15.4% increase since 2018.

In the past 8 years, China SXT Pharmaceuticals' cash and equivalents has ranged from $560.25 thousand in 2018 to $28.18 million in 2026, and is currently $28.18 million as of their latest financial filing in 2026.

Over the last 9 years, China SXT Pharmaceuticals' book value per share changed from 0.00 in 2017 to 43.71 in 2026, a change of 4,371.0%.

Related Companies

Financial statements for NASDAQ:SXTC last updated on 7/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

China SXT Pharmaceuticals (SXTC) Financials

Financials Breakdown Chart

China SXT Pharmaceuticals Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

China SXT Pharmaceuticals (SXTC) Financials

Annual Income Statements for China SXT Pharmaceuticals

Quarterly Income Statements for China SXT Pharmaceuticals

Annual Cash Flow Statements for China SXT Pharmaceuticals

Quarterly Cash Flow Statements for China SXT Pharmaceuticals

Annual Balance Sheets for China SXT Pharmaceuticals

Quarterly Balance Sheets for China SXT Pharmaceuticals

Annual Metrics And Ratios for China SXT Pharmaceuticals

Quarterly Metrics And Ratios for China SXT Pharmaceuticals

Financials Breakdown Chart

China SXT Pharmaceuticals Financials - Frequently Asked Questions

When does China SXT Pharmaceuticals' financial year end?

How has China SXT Pharmaceuticals' net income changed over the last 9 years?

What is China SXT Pharmaceuticals' operating income?

How has China SXT Pharmaceuticals' revenue changed over the last 9 years?

How much debt does China SXT Pharmaceuticals have?

How much cash does China SXT Pharmaceuticals have?

How has China SXT Pharmaceuticals' book value per share changed over the last 9 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools